ImmVira’s New-Generation Vector Poised to Enable CAR-T Treatment for Solid Tumors
SHENZHEN, China, Jan. 25, 2022 /PRNewswire/ -- Demonstrating innovation leadership on a global level, ImmVira announced that, its custom-designed new-generation oncolytic herpes simplex virus ("oHSV") vector enabling CAR-T treatment for solid tumors has started pilot-scale manufacturing and Pharmacological and toxicological studies for IND filing in both the U.S. and China. Solid...
IMPRESSION Randomized Trial: Past the halfway mark and progressing rapidly
SINGAPORE, Jan. 24, 2022 /PRNewswire/ -- Concept Medical Inc., focused on vascular intervention drug delivery devices, shares the latest status of its IMPRESSION (sIroliMus coated balloon angioPlasty versus plain balloon angioplasty in the tREatment of dialySis acceSs dysfunctION) randomized controlled trial (RCT), as it crosses the 50 per cent enrollment mark. ...
Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826
SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced the first patient dosing in its phase II clinical trial of KX-826("pyrilutamide") in China for the treatment of acne vulgaris. The clinical trial in China for the treatment of acne vulgaris was the fusion design...
MGI’s New MGISP-Smart 8 Automated Sample Preparation System Makes International Debut at MEDLAB Middle East
DUBAI, UAE, Jan. 24, 2022 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a global life science leader and innovator, has unveiled its new MGISP-Smart 8 automated sample preparation system to the world at MEDLAB Middle East, which kicked off today at the Dubai World Trade Center. The event marks the debut of the MGISP-Smart 8 in international markets outside of...
Zepp Health Releases 2021 Reports on User Health Status
CUPERTINO, Calif., Jan. 24, 2022 /PRNewswire/ -- A world-leading smart wearable brand, Zepp Health (NYSE: ZEPP), has recently released its 2021 Reports on User Health Status in five countries around the world. The reports contain key findings derived from the data of over 30 million global users, captured by the company's smart wearable devices in 2021. The data collected has been...
Samsung Biologics Reports Fourth Quarter & Fiscal Year 2021 Financial Results
Q4'21 revenue of KRW 444.3 billion increased 18% compared to Q4'20. Q4'21 operating profit of KRW 128.8 billion increased 39% compared to Q4'20. FY'21 revenue of KRW 1,568.0 billion, an increase of 35% compared to FY'20. FY'21 operating profit of KRW 537.3 billion, an increase of 84% compared to FY'20. Stable business operations and...
Harbour BioMed Announces Dosing of First Patient in Combination Therapy Phase Ib/IIa Trial of Next-Generation Anti-CTLA-4 Antibody
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) announced that, it has successfully completed the dosing of first patient in phase Ib/IIa trial at the stage of dose expansion of its anti-CTLA-4 antibody (HBM4003) in combination therapy with toripalimab (anti-PD-1 antibody) for...
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That...
SAN FRANCISCO and SUZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases announced that the Hong Kong Department of Health (DH) has approved Pemazyre® (pemigatinib) for the treatment of adults with locally advanced or...
Applied Pharmaceutical Science Inc. Announces FDA Approval of Investigational New Drug Application for APS03118, a Next generation RET Original New Drug for Unlimited Cancers
BEIJING and PHILADELPHIA, Jan. 24, 2022 /PRNewswire/ -- Applied Pharmaceutical Science, Inc. ("APS" or "the Company"), has recently announced the Investigational New Drug (IND) application for its self-developed breakthrough new drug APS03118, a next generation selective RET inhibitor, has been approved by the U.S. Food and Drug Administration (FDA). The clinical application is also in the process of...
Infinitus releases 2021 Corporate Social Responsibility Report
GUANGZHOU, China, Jan. 24, 2022 /PRNewswire/ -- Infinitus (China) Company, Ltd ("Infinitus") released its 2021 Corporate Social Responsibility (CSR) Report on January 18, 2022. This marks the 15th consecutive year that Infinitus has issued its CSR Report outlining the company's socially responsible practices. The report showed that Infinitus continued delivering on its deep commitment to health in 2021...
